The CNS as a target for peptides and peptide-based drugs

Bibliography

• BANKS WA, KASTIN AJ: CSF–plasma relationships for DSIP and some other neuropeptides. Pharmacol. Biochem. Behav. (1983) 19:1037-1040.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ: A brain-to-blood carrier-mediated transport system for small, N-tyrosinated peptides. Pharmacol. Biochem. Behav. (1984) 21:943-946.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ: Passage of peptides across the blood–brain barrier: pathophysiological perspectives. Life Sci. (1996) 59:1923-1943.
   PubMed Web of Science ®Google Scholar
• BEGLEY DJ: Strategies for delivery of peptide drugs to the central nervous system: exploiting molecular structure. J. Control. Release (1994) 29:293-306.
   Web of Science ®Google Scholar
• EGLETON RD, DAVIS TP: Bioavailability and transport of peptides and peptide drugs into the brain. Peptides (1997) 18:1431-1439.
   PubMed Web of Science ®Google Scholar
• KASTIN AJ, PAN W, ZADINA JE, BANKS WA: The endocrine brain. In: Principles and Practice of Endocrinology and Metabolism. Becker KL (Ed)., Lippincott Williams and Wilkins, Philadelphia, PA, USA ( 2001):1611-1615.
   Google Scholar
• PERRY T, GREIG NH: The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer’s disease. J. Alzheimer’s Dis. (2002) 4:487-496.
   PubMed Web of Science ®Google Scholar
• OLDENDORF WH: Lipid solubility and drug penetration of the blood–brain barrier. Proc. Soc. Exp. Biol. Med. (1974) 147:813-816.
   PubMed Web of Science ®Google Scholar
• LEVIN VA: Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. (1980) 23:682-684.
   PubMed Web of Science ®Google Scholar
• PAN W, KASTIIN AJ: Changing the chemokine gradient: CINC1 crosses the blood–brain barrier. J. Neuroimmunol. (2001) 115:64-70.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ, AKERSTROM V, JASPAN JB: Radioactively iodinated cyclo(His-Pro) crosses the blood–brain barrier and reverses ethanol-induced narcosis. Am. J. Physiol. (1993) 264:E723-E729.
   PubMed Web of Science ®Google Scholar
• BANKS WA, JUMBE NL, FARRELL CL, NIEHOFF ML, HEATHERINGTON A: Passage of erythropoietic agents across the blood–brain barrier: A comparison of human and murine erythropoietin and the analog darbopoetin alpha. Eur. J. Pharmacol. (2004) 505:93-101.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ: Peptide binding in blood and passage across the blood–brain barrier. In: Proceedings of the International Symposium on Blood Binding and Drug Transfer. Tillement JP, Eckert H, Albengres E, Barre J, Baumann P, Belpare F, Lemaire M (Eds), Fort and Clair, Paris, France (1993):223-242.
   Google Scholar
• BARANCZYK-KUZMA A, AUDUS KL: Characteristics of aminopeptidase activity from bovine brain microvessel endothelium. J. Cereb. Blood Flow Metab. (1987) 7:801-805.
   PubMed Web of Science ®Google Scholar
• BROWNSON EA, ABBRUSCATO TJ, GILLESPIE TJ, HRUBY VJ, DAVIS TP: Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. (1994) 270:675-680.
   PubMed Web of Science ®Google Scholar
• CORDON-CARDO C, O’BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86:695-698.
   PubMed Web of Science ®Google Scholar
• BEGLEY DJ: ABC transporters and the blood–brain barrier. Curr. Pharm. Des. (2004) 10:1295-1312.
   PubMed Web of Science ®Google Scholar
• SCHINKEL AH, WAGENAAR E, MOL CA, VAN DEEMTER L: P-Glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. (1996) 97:2517-2524.
   PubMed Web of Science ®Google Scholar
• DRACH J, GSUR A, HAMILTON G et al.: Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood (1996) 88:1747-1754.
   PubMed Web of Science ®Google Scholar
• LAM FC, LIU R, SHAPIRO AB, RENOIR JM, SHARON FJ, REINER PB: beta-Amyloid efflux mediated by P-glycoprotein. J. Neurochem. (2001) 76:1121-1128.
   PubMed Web of Science ®Google Scholar
• VOGELGESANG S, CASCORBI I, SCHROEDER E et al.: Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics (2002) 12:535-541.
   PubMedGoogle Scholar
• BANKS WA, KASTIN AJ: Editorial Review: Peptide transport systems for opiates across the blood–brain barrier. Am. J. Physiol. (1990) 259:E1-E10.
   PubMed Web of Science ®Google Scholar
• COURADE JP, BESSE D, DELCHAMBRE C et al.: Acetaminophen distribution in the rat central nervous system. Life Sci. (2001) 69:1455-1464.
   PubMed Web of Science ®Google Scholar
• ADVOKAT C, GULATI A: Spinal transection reduces both spinal antinociception and CNS concentration of systemically administered morphine in rats. Brain Res. (1991) 555:251-258.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ: Opposite direction of transport across the blood–brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine. Peptides (1994) 15:23-29.
   PubMed Web of Science ®Google Scholar
• BANKS WA: Are the extracellular pathways a conduit for the delivery of therapeutics to the brain? Curr. Pharm. Des. (2004) 10:1365-1370.
   Google Scholar
• NAKAOKE R, RYERSE JS, NIWA M, BANKS WA: Human immunodeficiency virus Type 1 transport across the in vitro mouse brain endothelial cell monolayer. Exp. Neurol. (2005) 193:101-109.
   PubMed Web of Science ®Google Scholar
• BANKS WA, PAGLIARI P, NAKAOKE R, MORLEY JE: Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins. Peptides (2005) 26:287-294.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ, COY DH: Delta sleep-inducing peptide crosses the blood-brain-barrier in dogs: some correlations with protein binding. Pharmacol. Biochem. Behav. (1982) 17:1009-1014.
   PubMed Web of Science ®Google Scholar
• RIANT P, URIEN S, ALBENGRES E, RENOUARD A, TILLEMENT JP: Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood–brain barrier. J. Neurochem. (1988) 51:421-425.
   PubMed Web of Science ®Google Scholar
• DREWES LR, CONWAY WP, GILBOE DD: Net amino acid transport between plasma and erythrocytes and perfused dog brain. Am. J. Physiol. (1977) 2:E320-E325.
   Google Scholar
• BANKS WA, GOULET M, RUSCHE J, NIEHOFF ML, BOISMENU R: Differential transport of secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J. Pharmacol. Exp. Ther. (2002) 302:1062-1069.
   PubMed Web of Science ®Google Scholar
• OUDE ELFERINK RP, ZADINA JE: MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides (2001) 22:2015-2020.
   PubMed Web of Science ®Google Scholar
• KING M, SU W, CHANG A, ZUCKERMAN A, PASTERNAK GW: Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat. Neurosci. (2001) 4:221-222.
   PubMed Web of Science ®Google Scholar
• BATRAKOVA EV, ZHANG Y, LI Y et al.: Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood–brain barrier. Pharm. Res. (2004) 21:1993-2000.
   PubMed Web of Science ®Google Scholar
• BROADWELL RD, BALIN BJ, SALCMAN M: Transcytotic pathway for blood-borne protein through the blood–brain barrier. Proc. Natl. Acad. Sci. USA (1988) 85:632-636.
   PubMed Web of Science ®Google Scholar
• BROADWELL RD: Transcytosis of macromolecules through the blood–brain barrier: a cell biological perspective and critical appraisal. Acta Neuropathol. (Berl.) (1989) 79:117-128.
   Google Scholar
• MCQUAY HJ, SULLIVAN AF, SMALLMAN K, DICKENSON AH: Intrathecal opioids, potency and lipophilicity. Pain (1989) 36:111-115.
   PubMed Web of Science ®Google Scholar
• MCCARTHY TJ, BANKS WA, FARRELL CL et al.: Positron emission tomography shows that intrathecal leptin reaches the hypothalamus in baboons. J. Pharmacol. Exp. Ther. (2002) 307:878-883.
   Web of Science ®Google Scholar
• LEBEL CP: Spinal Delivery of neurotrophins and related molecules. In: Spinal Drug Delivery. Yaksh TL (Ed.), Elsevier, Amsterdam, the Netherlands, (1999):543-554.
   Google Scholar
• LEBEL C, BOURDEAU A, LAU D, HUNT P: Biological response to peripheral and central administration of recombinant human leptin in dogs. Obes.Res. (1999) 7:577-585.
   PubMedGoogle Scholar
• BORN J, LANGE T, KERN W, MCGREGOR GP, BICKEL U, FEHM HL: Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. (2002) 5:514-516.
   PubMed Web of Science ®Google Scholar
• DURING MJ, CAO L, ZUZGA DS et al.: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. (2003) 9:1173-1179.
   PubMed Web of Science ®Google Scholar
• DUFES C, OLIVIER JC, GAILLARD F, GAILLARDA, COUET W, MULLER JM: Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int. J. Pharmaceut. (2003) 255:87-97.
   PubMed Web of Science ®Google Scholar
• FREY WH II: Bypassing the blood–brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. (2002) 2:46-49.
   Google Scholar
• BANKS WA, DURING MJ, NIEHOFF ML: Brain uptake of glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J. Pharmacol. Exp. Ther. (2004) 309:469-475.
   PubMed Web of Science ®Google Scholar